Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05225259|
Expanded Access Status : Available
First Posted : February 4, 2022
Last Update Posted : February 4, 2022
Expanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor.
Participants do not qualify for an ongoing LOXO-260 clinical trial or have other considerations that prevent access to LOXO-260 through an existing clinical trial.
The treating physician/investigator contacts Loxo Oncology, Inc. when, based on their medical opinion, a patient meets the criteria for expanded access.
|Condition or disease||Intervention/treatment|
|Carcinoma, Non-Small-Cell Lung Thyroid Neoplasms||Drug: LOXO-260|
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|See clinical trials of the intervention/treatment in this expanded access record.|
|Official Title:||Expanded Access of LOXO-260 in Participants With RET Mutant or RET Fusion Tumors Refractory to Prior RET Selective TKI Treatment|
- Drug: LOXO-260
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05225259
|Contact: Patient Advocacy||1-855-LOXOemail@example.com|
|Study Director:||Emin Avsar, MD||Loxo Oncology, Inc.|